Navigation Links
ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma

of institutions on the East Coast to one of the largest clinical cancer research organizations in the U.S. with almost 6000 physicians, nurses, pharmacists, statisticians, and clinical research associates (CRAs) from the U.S., Canada, and South Africa. Institutional members include universities, medical centers, Community Clinical Oncology Programs (CCOPs), and Cooperative Group Outreach Programs (CGOPs). These institutions work toward the common goal of controlling, effectively treating, and ultimately curing cancer. Research results are provided to the worldwide medical community through scientific publications and professional meetings

About Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the Company's website at http://www.celgene.com.

REVLIMID(R) and RevAssist(R) are registered trademarks of Celgene Corporation.

This release contains forward-looking statements which are subject to known and unknown risks, delays, uncertainties and other factors not under the Company's control, which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements. These factors include results of current or pending research and development activities, actions by the FDA and other regulatory authorities, and other factors described in the Company's filings with the Securities and Exchange Commission such as our 10K, 10Q and 8K reports.

CONTACT: David W. Gryska, Sr. Vice President and Chief Financial Officer,+1-908-673-9059, or Brian P. Gill, Vice President, CorporateCom
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:7/24/2014)...  Restore Health, a leading personalized medicine company ... it is now offering pharmacogenetics testing that provides ... upon their particular genetic makeup. Comprehensive medication management ... a patient,s genetics and their entire drug regimen.  ... this new service to healthcare providers and their ...
(Date:7/24/2014)... UNION CITY, Calif., July 24, 2014  Abaxis, Inc. ... manufacturing point-of-care blood analysis systems, today reported financial results ... First quarter overview: , Revenues of ... , Diluted EPS of $0.21, up 50% over ... , Medical market revenues of $7.2 million, up 20% ...
(Date:7/24/2014)... 2014 Omnicell, Inc. (NASDAQ: ... supply management solutions and analytics software for healthcare ... to discuss the Company,s Second Quarter 2014 financial ... earnings conference call and webcastWhen: , July ... chairman, president and chief executive officer ...
Breaking Medicine Technology:Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2
... , WASHINGTON, Dec. 10 BioWorld Today ... Research and Manufacturers of America ( PhRMA ) that identifies 97 new ... conditions. , The report , which was released ahead of ... found that the 97 products in development include 23 vaccines and 54 ...
... , MILFORD, Mass., Dec. 10 ... that it is partnering with the NC BioNetwork Pharmaceutical ... NC, to educate and train students and workers in ... biopharmaceutical industry. The Pharmaceutical Center, which is a collaborative ...
Cached Medicine Technology:Nearly 100 HIV/AIDS Drugs and Vaccines in Development Pipeline 2New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 2New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 4
(Date:7/27/2014)... Bags underneath the eyes is one condition ... there are a range of new products now available from ... baggy eyes serum review that is now posted for adults ... the issues with baggy eyes and how the natural ingredients ... The guide also provides a detailed overview of the creams ...
(Date:7/27/2014)... The report, “Glass Fiber & ... Raw Material, By Manufacturing Process, By Application (Transportation, ... Geography – Global Trends & Forecast to 2019”, ... with an analysis and forecast by value and ... 107 figures spread through 347 slides and in-depth ...
(Date:7/27/2014)... Prominent Vancouver Chiropractors, Dr. Shervin Ranjbar and ... hamstring release procedure in Vancouver, BC. Both these chiropractors ... and have years of experience in the field of ... by the two professionals using a foam roller exercise. ... release tight hamstrings and relieve the client of the ...
(Date:7/27/2014)... City (Sunday July 27 11:45 am ET): ... at the surgical sitehas been reduced by 77 ... in the American College of Surgeons National Surgical ... new case study presented at the 2014 ACS ... British Columbia, reportedly reduced its rate of cardiac ...
(Date:7/27/2014)... 2014 Metachromatic leukodystrophy (MLD, also ... disease which is commonly listed in the family ... as it affects the metabolism of sphingolipids. Leukodystrophies ... fatty covering which acts as an insulator around ... systems. MLD involves cerebroside sulfate accumulation. Metachromatic leukodystrophy, ...
Breaking Medicine News(10 mins):Health News:Baggy Eyes Serum Review Posted for Men and Women at Cherry News Website 2Health News:Major Drivers for GFRP Composites Market in Future – Report by MarketsandMarkets 2Health News:Major Drivers for GFRP Composites Market in Future – Report by MarketsandMarkets 3Health News:Major Drivers for GFRP Composites Market in Future – Report by MarketsandMarkets 4Health News:Renowned Vancouver Chiropractors Demonstrates Hamstring Release in Vancouver, BC 2Health News:Surgical safety program greatly reduces surgical site infections for heart operations 2Health News:Surgical safety program greatly reduces surgical site infections for heart operations 3Health News:Surgical safety program greatly reduces surgical site infections for heart operations 4Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 2Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 3Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 4Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 5
... Hospital today became the first in Ontario to implant a small ... about the size of a Zippo lighter is the ... highest level of energy, 40 joules. The narrow shape ... incision in the patient,s chest, which should mean a faster recovery ...
... , TUESDAY, Dec. 21 (HealthDay News) -- Like ... their sex, say researchers who spent 14 years observing a ... researchers found that both male and female chimpanzee youngsters play ... treat the sticks as would mothers caring for their infants. ...
... , TUESDAY, Dec. 21 (HealthDay News) -- Children ... independent in adulthood, new study findings suggest. For example, ... shoes in the bedroom or apples in the supermarket, according ... Kingdom. The study authors asked 20 children with autism ...
... , HOUSTON, Dec. 21, 2010 The day when an ... painless pill instead of a toxic drug cocktail is the ... Houston (UH) scientist. Preethi Gunaratne, assistant professor in ... of tiny genetic molecules known as microRNAs and pinpointing those ...
... morbidly obese persons face many health issues -- heart disease, ... chances of dying while driving during a severe auto accident ... vehicle crash, a moderately obese driver faces a 21 percent ... 56 percent increased risk of not surviving, according to a ...
... By Jenifer Goodwin HealthDay Reporter , TUESDAY, ... discovered in recent years, losing a job is upsetting and ... But buck up. About a year later, the majority ... returned to their previous levels of happiness, a new study ...
Cached Medicine News:Health News:Young Female Chimps Use Sticks as 'Dolls' 2Health News:UH biochemist works to revolutionize ovarian cancer treatment 2Health News:UH biochemist works to revolutionize ovarian cancer treatment 3Health News:UH biochemist works to revolutionize ovarian cancer treatment 4Health News:Obesity increases risk of death in severe vehicle crashes, study shows 2Health News:Most People Regain Happiness After Job Loss 2Health News:Most People Regain Happiness After Job Loss 3
BD Vacutainer® PST™ Tubes contain spray-coated lithium heparin and a gel for plasma separation. They are used for plasma determinations in chemistry....
The Erythrocyte Sedimentation Rate (ESR) can be used as a nonspecific search technique in case of suspicion of inflammatory reactions as well as for judgement of their development. VACUETTE ESR tubes...
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
Glucose tubes contain an anti-coagulant and a stabiliser. The tubes are ideal for glucose and lactate determinations....
Medicine Products: